Search Results
–1406. [Hungarian] 12 Bollineni, V. R., Koole, M. J., Pruim, J., et al.: Dynamics of tumor hypoxia assessed by 18 F-FAZA PET/CT in head and neck and lung cancer patients
164 1233 1241 Weston, A., Godbold, J. H.: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ
127 160 171 Bray, F. I., Weiderpass, E.: Lung cancer mortality trends in 36 European countries: secular trends and birth cohort
-validation of COPD biomarkers in a single step. Electrophoresis 2007; 28: 4401–4406. 11 Indovina P, Marcelli E, Maranta P, et al. Lung cancer proteomics: recent advances in biomarker
metastases from lung cancer. Integrative Cancer Therapies, 2008, 7 , 172–181. Somlyai G. A retrospective evaluation of the effects of deuterium depleted water consumption on four
cancer to gefitinib. N. Engl. J. Med., 2004, 350 , 2129–2139. Sordella R. Activating mutations in the Epidermal Growth Factor Receptor underlying responsiveness of non-small-cell lung
obstructive pulmonary disease and lung cancer in Chinese. PLoS One 7, e46071 (2012) Lu J. Functional polymorphisms of CHRNA3 predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese PLoS One
-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat. Oncol., 2006, 1, 30. 13 Habermehl, D., Herfarth, K. K., Bermejo, J. L., et al.: Single
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumanoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 , 189
. 27 Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015; 27: 108–117. 28 Wu K, House L, Liu W
